IsoPlexis completed $13.5 million in Series B financing. Spring Mountain Capital led the round,  with participation from Connecticut Innovations, Ironwood Capital, and North Sound Ventures. IsoPlexis is a life sciences company that is developing a cellular response analysis platform that identifies a wide range of patient